



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

| APPLICATION NUMBER | FILING OR 371 (c) DATE | FIRST NAMED APPLICANT | ATTORNEY DOCKET NUMBER |
|--------------------|------------------------|-----------------------|------------------------|
| 10/647,732         | 08/25/2003             | Thomas T. Chen        | 30471.59292(CON)       |

21874

EDWARDS & ANGELL, LLP  
P.O. BOX 9169  
BOSTON, MA 02209

CONFIRMATION NO. 2152

## FORMALITIES LETTER



\*OC000000011356409\*

Date Mailed: 11/25/2003

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

*Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- o This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

Replies should be mailed to: Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450

Alexandria VA 22313-1450

---

*A copy of this notice MUST be returned with the reply.*

  
\_\_\_\_\_  
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

|              |   |                              |
|--------------|---|------------------------------|
| Applicants:  | Thomas T. Chen<br>Maria M.J. Chen                   | Art Unit: 1653               |
| For:         | ANTI-TUMOR ACTIVITY OF EA-4<br>PEPTIDE OF PRO-IGF-1 | Examiner: Unknown            |
| Serial No.:  | 10/647,732  | Atty. Docket No: 30471-59292 |
| Filing Date: | August 25, 2003                                     |                              |

Mail Stop: Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RESPONSE TO NOTICE TO COMPLY AND STATEMENT OF CONFORMITY

In response to the Notice to Comply mailed November 25, 2003 with respect to patent applications containing amino acid or nucleic acid sequences or sequence disclosures, applicants submit herewith a copy of the "Sequence Listing" in computer readable form as required under 37 C.F.R. §§ 1.821-1.825. A Preliminary Amendment with a paper form of the sequence is being filed herewith.

The content of the sequence listing information recorded in computer readable form is identical to the paper copy of the written sequence and includes no new matter as required by 37 C.F.R. 1.821(e-g) or 1.825(b) or 1.825(g).

No fee is believed to be due with this response; however, should a fee be required, authorization is given to charge Edwards & Angell Deposit Account No. 04-1105.

Respectfully submitted,

*Barbara S. Kitchell*

Barbara S. Kitchell, Registration No. 33,928  
Edwards & Angell LLP  
301 Tresser Blvd.  
Stamford, CT 06901  
(203) 353-6848  
(203) 975-7180

**CERTIFICATE OF MAILING:** I hereby certify that this correspondence is being deposited with the United States Postal Service as "First Class Mail" in an envelope addressed to: Mail Stop: MISSING PARTS, Commissioner for Patents, P.O. Box 1450, Arlington, VA 22313-1450.

Name *[Signature]*

Date *12/9/03*